Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-acetylcysteine or placebo Clear all
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 1, 2026, 9:27 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Use of NAC in Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol

NCT03104959
View directory record Official record
Conditions
Prevention of Hangover Using N-Acety Cysteine
Interventions
N-acetyl cysteine, placebo
Dietary Supplement · Other
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 1, 2026, 9:27 PM EDT
Recruiting Phase 2Phase 3 Interventional

BabySTrong II taVNS Feeding Trial

NCT07049952
View directory record Official record
Conditions
Feeding Delays, Neonates and Term Infants
Interventions
taVNS, NAC and taVNS, inactive taVNS, sterile water and inactive taVNS
Device · Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
39 Weeks to 54 Weeks
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

NCT01537081
View directory record Official record
Conditions
Acute Upper Respiratory Tract Infection
Interventions
Mucinex, Immediate-release Guaifenesin, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
12 Years and older
Enrollment
2,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Hoover, Alabama • Bell Gardens, California • Harbor City, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

NCT05798481
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neurocircuit Strategy to Decrease Cocaine Cue Reactivity

NCT04155632
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
N-acetylcysteine, Theta-burst stimulation (TBS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder

NCT03008889
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
5 Years to 12 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

NCT02966873
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions
N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432
View directory record Official record
Conditions
Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions
Glutathione, N-Acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132
View directory record Official record
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 4 Interventional

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCT02505477
View directory record Official record
Conditions
Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
Interventions
N-acetylcysteine, Treatment as Usual
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine for Tobacco Use Disorder

NCT02737358
View directory record Official record
Conditions
Nicotine Dependence, Smoking
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes

NCT02206152
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

NCT02123511
View directory record Official record
Conditions
Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Basal Cell Carcinoma of the Lip, Stage II Lymphoepithelioma of the Nasopharynx, Stage II Lymphoepithelioma of the Oropharynx, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
acetylcysteine, placebo, quality-of-life assessment, questionnaire administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

NCT01797575
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of N-Acetyl Cysteine in Children With Autism

NCT00627705
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine, Placebo - sugar pill
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Rifaximin With NAC in IBS-D

NCT04557215
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, N-acetylcysteine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Sinusitis

NCT00377403
View directory record Official record
Conditions
Acute Respiratory Infections, Acute Rhinosinusitis
Interventions
Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 1, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

NCT01322009
View directory record Official record
Conditions
Pediatric Traumatic Brain Injury
Interventions
Probenecid and N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
2 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 1, 2026, 9:27 PM EDT